张伟娟｜复旦大学｜学者主页

2026

Abstract CT057: Preliminary results from the first-in-human study of MK-2010, a PD-1×VEGF bispecific antibody

Jin Li, Wei-Zheng Kou, Long-Hua Sun, Yan-Qiu Zhao, Ru-Sen Zhao, Baozhong Wang, Shao-Zhang Zhou, Juan Li, Xue-Wen Liu, Jun Zhao, Dong-Qing Lv, Gaofeng Li, Junli Xue, Yong Fang, Daren Lin, Jian-Hua Shi, Yi Gong, X. Qin, Yi Zuo, Erik H. Knelson, Weijuan Zhang, Cai-Cun Zhou

Cancer Research

精选作品

期刊论文

Abstract CT057: Preliminary results from the first-in-human study of MK-2010, a PD-1×VEGF bispecific antibody

TP53 mutation-biased CD8+ T cell exhaustion drives lethal outcome and therapy resistance in urothelial carcinoma

Proliferative ecotype determines lethal prognosis and therapeutic benefit in urothelial carcinoma

Lethal clinical outcome and immuno-fibrotic contexture in refractory urothelial carcinoma harboring MYC amplification and overexpression

Aberrant p53 fuels macrophage immunoregulatory polarization and refractory clinical outcome in urothelial carcinoma

Natural killer cell infiltration elicits gender‐dependent dichotomous clinical outcomes in urothelial carcinoma

ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma

Lethal clinical outcome and chemotherapy and immunotherapy resistance in patients with urothelial carcinoma with MDM2 amplification or overexpression

RAD51 Expression as a Biomarker to Predict Efficacy of Platinum-Based Chemotherapy and PD-L1 Blockade for Muscle-Invasive Bladder Cancer

Integrating molecular subtype and CD8+ T cells infiltration to predict treatment response and survival in muscle-invasive bladder cancer

Integration of CD4+ T cells and molecular subtype predicts benefit from PD‐L1 blockade in muscle‐invasive bladder cancer

TP53 disruptive mutation predicts platinum‐based chemotherapy and PD‐1 / PD‐L1 blockade response in urothelial carcinoma

Blockade of V‐domain immunoglobulin suppressor of T‐cell activation reprograms tumour‐associated macrophages and improves efficacy of PD‐1 inhibitor in gastric cancer

POLQ identifies a better response subset to immunotherapy in muscle‐invasive bladder cancer with high PD‐L1

Gender disparities in clinical outcomes of urothelial carcinoma linked to X chromosome gene KDM6A mutation

Erratum to “Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion” [Eur. Urol. 75(5) (2019) 752–763]

Integrating angiogenesis signature and tumor mutation burden for improved patient stratification in immune checkpoint blockade therapy for muscle-invasive bladder cancer

Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer

Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy

Integrative tumour mutation burden with CD39 and PD-L1 for the prediction of response to PD-L1 blockade and adjuvant chemotherapy in muscle-invasive bladder cancer patients

Author Correction: EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma

Intratumoral Foxp3+RORγt+ T cell infiltration determines poor prognosis and immunoevasive contexture in gastric cancer patients

CD47 expression in gastric cancer clinical correlates and association with macrophage infiltration

Immune inactivation by APOBEC3B enrichment predicts response to chemotherapy and survival in gastric cancer

Intratumoral TIGIT+ CD8+ T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer

Poor Clinical Outcomes and Immunoevasive Contexture in Intratumoral IL-10-Producing Macrophages Enriched Gastric Cancer Patients

Tumor-infiltrating CD39+CD8+ T cells determine poor prognosis and immune evasion in clear cell renal cell carcinoma patients

CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma

Identification and validation of an immunogenic subtype of gastric cancer with abundant intratumoural CD103+CD8+ T cells conferring favourable prognosis

Lauren classification identifies distinct prognostic value and functional status of intratumoral CD8+ T cells in gastric cancer

Poor clinical outcomes of intratumoral dendritic cell–specific intercellular adhesion molecule 3–grabbing non-integrin–positive macrophages associated with immune evasion in gastric cancer

Blockade of DC-SIGN+ Tumor-Associated Macrophages Reactivates Antitumor Immunity and Improves Immunotherapy in Muscle-Invasive Bladder Cancer

Intratumoral CD103 + CD4 + T cell infiltration defines immunoevasive contexture and poor clinical outcomes in gastric cancer patients

Intratumoral interleukin-9 delineates a distinct immunogenic class of gastric cancer patients with better prognosis and adjuvant chemotherapeutic response

Identification and validation of an excellent prognosis subtype of muscle-invasive bladder cancer patients with intratumoral CXCR5 + CD8 + T cell abundance

“医学免疫学”形成性评价实践

PAK1 expression determines poor prognosis and immune evasion in metastatic renal cell carcinoma patients

Tumor-associated macrophages expressing galectin-9 identify immunoevasive subtype muscle-invasive bladder cancer with poor prognosis but favorable adjuvant chemotherapeutic response

Intratumoral IL22‐producing cells define immunoevasive subtype muscle‐invasive bladder cancer with poor prognosis and superior nivolumab responses

Tumor infiltrating mast cells determine oncogenic HIF-2α-conferred immune evasion in clear cell renal cell carcinoma

Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer

Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion

CD19+ tumor-infiltrating B-cells prime CD4+ T-cell immunity and predict platinum-based chemotherapy efficacy in muscle-invasive bladder cancer

医学免疫学实践性教学探索

Association of O6-Methylguanine-DNA Methyltransferase Protein Expression With Postoperative Prognosis and Adjuvant Chemotherapeutic Benefits Among Patients With Stage II or III Gastric Cancer

Tumor-infiltrating γδT cells predict prognosis and adjuvant chemotherapeutic benefit in patients with gastric cancer

Beta-1,4-galactosyltransferase II predicts poor prognosis of patients with non-metastatic clear-cell renal cell carcinoma

Loss of N-Acetylgalactosaminyltransferase-4 Orchestrates Oncogenic MicroRNA-9 in Hepatocellular Carcinoma

CXC chemokine receptor 1 predicts postoperative prognosis and chemotherapeutic benefits for TNM II and III resectable gastric cancer patients

Low Expression of Mucin-4 Predicts Poor Prognosis in Patients With Clear-Cell Renal Cell Carcinoma

High expression of C-C chemokine receptor 2 associates with poor overall survival in gastric cancer patients after surgical resection

IL-33 is associated with unfavorable postoperative survival of patients with clear-cell renal cell carcinoma

Elevated expression of IFN-inducible CXCR3 ligands predicts poor prognosis in patients with non-metastatic clear-cell renal cell carcinoma

Decreased expression of Siglec-8 associates with poor prognosis in patients with gastric cancer after surgical resection

Prognostic significance of ubiquinol-cytochrome c reductase hinge protein expression in patients with clear cell renal cell carcinoma.

Positive intratumoral chemokine (C-C motif) receptor 8 expression predicts high recurrence risk of post-operation clear-cell renal cell carcinoma patients

High expression of Solute Carrier Family 1, member 5 (SLC1A5) is associated with poor prognosis in clear-cell renal cell carcinoma

Prognostic value of interleukin-6 and interleukin-6 receptor in organ-confined clear-cell renal cell carcinoma: a 5-year conditional cancer-specific survival analysis

Decreased Expression of SETD2 Predicts Unfavorable Prognosis in Patients With Nonmetastatic Clear-Cell Renal Cell Carcinoma

High Expression of Colony-Stimulating Factor 1 Receptor Associates with Unfavorable Cancer-Specific Survival of Patients with Clear Cell Renal Cell Carcinoma

Tumor Suppressive Function of p21-activated Kinase 6 in Hepatocellular Carcinoma

EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma

P2X7 receptor predicts postoperative cancer‐specific survival of patients with clear‐cell renal cell carcinoma

Prognostic significance of β1,6-N-acetylglucosaminyltransferase V expression in patients with hepatocellular carcinoma

p21-Activated kinase 4 predicts early recurrence and poor survival in patients with nonmetastatic clear cell renal cell carcinoma

Prognostic value of purinergic P2X7 receptor expression in patients with hepatocellular carcinoma after curative resection

Galectin-9 predicts postoperative recurrence and survival of patients with clear-cell renal cell carcinoma

High expression of interleukin‐11 is an independent indicator of poor prognosis in clear‐cell renal cell carcinoma

Increased expression of colony stimulating factor-1 is a predictor of poor prognosis in patients with clear-cell renal cell carcinoma

β1,6-N-acetylglucosaminyltransferase V predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection

Decreased Expression of Hepatocyte Nuclear Factor 4α (Hnf4α)/MicroRNA-122 (miR-122) Axis in Hepatitis B Virus-associated Hepatocellular Carcinoma Enhances Potential Oncogenic GALNT10 Protein Activity

Elevated Expression of N-Acetylgalactosaminyltransferase 10 Predicts Poor Survival and Early Recurrence of Patients with Clear-Cell Renal Cell Carcinoma

Galectin-8 predicts postoperative recurrence of patients with localized T1 clear cell renal cell carcinoma

Snail predicts recurrence and survival of patients with localized clear cell renal cell carcinoma after surgical resection

Tumor mi R ‐125b predicts recurrence and survival of patients with clear‐cell renal cell carcinoma after surgical resection

GALNT4 Predicts Clinical Outcome in Patients with Clear Cell Renal Cell Carcinoma

Prognostic Significance of p21-activated Kinase 6 Expression in Patients with Clear Cell Renal Cell Carcinoma

Prognostic Value of Diametrically Polarized Tumor-Associated Macrophages in Renal Cell Carcinoma